SUSTIVA™ (efavirenz) in combination with other antiretroviral agents is indicated for the treatment of HIV-1 infection. This indication is based on analyses of plasma HIV-RNA levels and CD4 cell counts in controlled studies of up to 24 weeks in duration. At present, there are no results from controlled trials evaluating long-term suppression of HIV-RNA with SUSTIVA™.
Resistant virus emerges rapidly when non-nucleoside reverse transcriptase inhibitors (NNRTIs) are administered as monotherapy. Therefore, SUSTIVA™ must not be used as a single agent to treat HIV or added on as a sole agent to a failing regimen. SUSTIVA™ therapy should always be initiated in combination with at least one other antiretroviral agent to which the patient has not been previously exposed.
News about Sustiva: FDA Approves Sustiva (efavirenz) Capsules, First Once-daily Anti-HIV Drug
Go to the NNRTI Menu
Go to the Treatments for HIV/AIDS Menu
Go to the HIVpositive.us Main Menu